PubRank

Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC (ESR1814205)

Clinical Trial ID NCT04441138

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04441138

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012 52.99
2 Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012 35.24
3 The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012 24.94
4 Signatures of mutational processes in human cancer. Nature 2013 21.63
5 PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008 19.24
6 Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013 17.53
7 Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002 12.39
8 MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014 10.49
9 Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014 9.86
10 Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007 8.94
11 The three Es of cancer immunoediting. Annu Rev Immunol 2004 8.20
12 Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008 8.17
13 Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005 4.94
14 Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008 3.18
15 Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A 2011 2.90
16 The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol 2011 2.69
17 Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol 2011 1.40
18 Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 2006 1.26
19 Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol 2009 1.26
20 Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 2009 1.25
21 Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol 2011 1.06
22 Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res 2015 1.01
23 Fixed dosing versus body size-based dosing of therapeutic peptides and proteins in adults. J Clin Pharmacol 2011 0.89
24 Analysis of duration of response in oncology trials. Contemp Clin Trials 2007 0.85
25 Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol 2016 0.85
26 Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus. Clin Pharmacokinet 2013 0.82
27 Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. Cancer Med 2016 0.80
28 Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy. Pract Radiat Oncol 2014 0.79
29 Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1-IgV. Cytotherapy 2008 0.78
30 Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017 0.75
31 Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy. Lung Cancer 2017 0.75
32 Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol 2017 0.75
Next 100